Navigation Links
Block Engineering Announces Collaborative Agreement with Pfizer for Next Generation Cleaning Verification Technology
Date:1/18/2013

MARLBOROUGH, Mass., Jan. 18, 2013 /PRNewswire/ -- Block Engineering, the leader in Quantum Cascade Laser (QCL) spectroscopy, announced today that it has signed a Collaborative Agreement with Pfizer, Inc. to develop a QCL-based system for real-time, noncontact Cleaning Verification of vessels during pharmaceutical manufacturing. The technology is based on Block's commercially available LaserScan (TM) Analyzer, which will be tailored to address the specific requirements of this application.

Accurate Cleaning Verification of vessels has a significant impact in pharmaceutical manufacturing, due to the potential health risks of cross-contamination between products. Today, in order to ensure that the walls of these vessels meet tough FDA cleanliness standards, swab-based techniques are applied to collect samples and bring them to off-line instruments, such as High Pressure Liquid Chromatography (HPLC) systems. These measurements typically take several hours or more per vessel during which the vessel usually remains idle. The key value proposition of the proposed technology is to eliminate this bottleneck and provide a handheld, battery-operated, barcode-scanner-like device capable of providing real-time, noncontact verification of the cleanliness of the vessel walls. Using the proposed technology, pharmaceutical manufacturing equipment could be scanned in a matter of minutes and potential areas that require additional cleaning will be identified in real-time without the need to take any samples. Block's device requires no consumables and utilizes next generation, eye-safe QCL-based infrared spectroscopy.

"Cleaning Verification is a critical step in the drug manufacturing process and Pfizer is committed to the development of technologies that could decrease inspection times, reduce costs and improve supply assurance," said Steve Hammond , Head of the Process Analytical Sciences Group (PASG) and Senior Director in the Global Manufacturing Services organization at Pfizer. "Block's groundbreaking technology fits well within Pfizer's Process Analytical Technology (PAT) initiatives and I look forward to working with them towards the development of this instrument."

The expected benefits of this novel approach include a reduction in the labor, material and consumables required today for swab-based verification. Furthermore, significant plant utilization increases can be achieved and drug supply assurances can be confidently offered. Key initiatives in the pharmaceutical industry today for Work-in-Progress inventory reduction and just-in-time-inventory implementation will significantly benefit from the proposed technology, as the manufacturing equipment idle time is reduced.

Petros Kotidis , CEO of Block Engineering commented, "I am very pleased to announce the strategic agreement with Pfizer towards the development of this breakthrough instrumentation. Block's QCL-based infrared spectrometers are opening new markets and Cleaning Verification is one of the most exciting and high impact applications. Pfizer's dominant and pioneering position in the introduction of next generation process analytical technologies will be a critical element in the success of this product."

The fundamental principle behind Block's technology and the currently commercially available LaserScan Analyzer is QCL-based infrared spectroscopy. When infrared light from the QCL reflects off of substances, it gets absorbed or reflected at rates that are absolutely unique to and characteristic of the substance. Therefore, when the reflected light is collected by the LaserScan's built-in detectors, a "fingerprint"-like pattern emerges, which contains all the necessary information for detection or analysis of the substance. Built-in libraries are typically used to pattern and provide real-time detection or analysis. Block's devices use unique QCLs, which cover the widest spectral range in the world within the 5-14 micron range and provide rapid sub-second, real-time measurements in handheld configurations.

About Block Engineering, LLC:
Founded in 1956, Block Engineering, LLC is a leading manufacturer and marketer of high performance Quantum Cascade Laser (QCL) and FTIR spectrometers for commercial, industrial, military and government customers. Block's Mobile Chemical Agent Detector (MCAD) system is a fixed site, passive FTIR spectrometer offered in partnership with Northrop Grumman Corp.  Block's PORTHOS (TM) is a portable, passive FTIR spectrometer system that remotely detects chemical threats as far as three miles and protects against chemical warfare agents and weapons of mass destruction. Block Engineering is also manufacturing and selling a line of unique QCL-based spectrometers, including the LaserScan Analyzer, for applications ranging from detection of explosives and liquid/solid chemical warfare agents to control of manufacturing operations and verification of surface conditions in a variety of industrial processes.

Block Engineering is located in Marlborough, Massachusetts, USA. For more information, visit www.blockeng.com.

Contact: Scott Riggi , Vice President of Sales, 508-251-3105, scott.riggi@blockeng.com

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.

 


'/>"/>
SOURCE Block Engineering
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
2. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
3. Block Engineering Partners with SKAE and Pembroke for Quantum Cascade Laser Instrument Sales
4. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
5. Kentuckys PSE Blocking Technology Leading To Progress In Battle Against Meth
6. Missouris PSE Blocking Technology Leading To Progress In Battle Against Meth
7. Austen BioInnovation Institute in Akron Attracts Nationally Known Speakers For Conference on Value-driven Engineering, April 23-24
8. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
9. Swiss Engineering for Surgical Perfection
10. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
11. American Oriental Bioengineering Announces Change of Independent Auditors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... , July 26, 2017 E.I. Medical Imaging ... the Bimini SharkLab to custom design the worlds first ultrasound system ... sharks in their native habitat. In preparation for a ... Channel,s Shark Week, Dr. Guttridge approached EIMI with the ... diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... services business of UnitedHealth Group (NYSE: UNH), has made a multi-million dollar partnership ... affected by post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) over the ...
(Date:8/20/2017)... ... ... Are you an adult with gluten intolerance or Celiac disease living with ... participating in a research study that focuses on family interactions when dealing with dietary ... aspects of adults who have gluten sensitivities who cohabitate with other adults who may ...
(Date:8/19/2017)... , ... August 19, 2017 , ... ... that it is the first organization with pending recognition status from the Centers ... Program (“DPP”) via group telehealth classes and live video conferencing. , The ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... joined its Orlando location as an interventional pain management physician. He brings a ... the treatment of migraine headaches, and significant experience in spinal cord stimulation for ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport ... a definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner ...
Breaking Medicine News(10 mins):